Articles from Junevity

Junevity, a biotechnology company on a mission to extend lifespan and healthspan with siRNA therapeutics, today announced a partnership with Sunrise BioVentures (“Sunrise”), a leading RNA therapeutics accelerator. Sunrise leadership comprises RNA veterans Andrew Fraley, Ph.D., Rachel Meyers, Ph.D., Stuart Milstein, Ph.D., and Laurence Reid, Ph.D., who focus on the rapid advancement of novel oligonucleotide therapeutics and platforms. The Sunrise team brings decades of experience spanning the discovery and development of siRNA and other nucleic acid therapeutics at pioneering companies, including Alnylam Pharmaceuticals, Korro Bio, Judo Bio and Decibel Therapeutics.

Junevity, a biotechnology company on a mission to extend lifespan and healthspan with siRNA (silencing RNA) therapeutics, today announced co-founder and chief scientific officer Dr. Janine Sengstack will be presenting the first ever data demonstrating that siRNA therapeutics can restore global gene networks to a healthier state. The data will be featured during an oral presentation at the American Aging Association’s Annual Meeting on at 3:45 p.m. MDT on Weds, June 3rd in Provo, Utah.

Junevity, a biotechnology company on a mission to extend lifespan and healthspan with cell reprogramming, today announced the publication of a peer-reviewed study in Proceedings of the National Academy of Sciences (PNAS) validating that precise modulation of individual transcription factors can reverse core hallmarks of cellular aging and restore tissue function in vivo. The paper covers systemic identification of transcription factors for cell and tissue rejuvenation. The findings form the scientific foundation for Junevity’s RESET platform and longevity-focused therapeutic programs, including JUN_01, the company’s lead siRNA (silencing RNA) candidate for type 2 diabetes and obesity.

Junevity, a biotechnology company on a mission to extend lifespan and healthspan with cell reprogramming, raised $10 million in new funding, bringing its Seed financing to a total of $20 million. The new funding, led by Goldcrest Capital and Godfrey Capital, enables Junevity to advance the company’s lead siRNA (silencing RNA) program for type 2 diabetes and obesity, JUN_01, through IND-enabling and initial clinical studies. The founders of Junevity were the first to demonstrate that repressing a single transcription factor can reprogram cell state to health in human cell models.

Junevity, a biotechnology company on a mission to extend lifespan and healthspan by resetting cell damage from age-related diseases, today announced $10 million in seed funding led by Goldcrest Capital and Godfrey Capital.